Bridging the Gaps in HIV Treatment: Progress and Future Challenges

This article was exclusively written for The European Sting by Ms. Hibatallah EL OMARI, a 4th year medical student at Mohammed VI University of Health Sciences in Casablanca, Morocco. She is affiliated with the International Federation of Medical Students Associations (IFMSA), cordial partner of The Sting. The opinions expressed in this piece belong strictly to the writer and do not necessarily reflect IFMSA’s view on the topic, nor The European Sting’s one.

The Initiation of a Global Health Crisis

On June 5, 1981, a report detailed five homosexual men diagnosed with Pneumocystis carinii pneumonia. Subsequent investigations revealed that these cases, along with numerous others, were linked to the Human Immunodeficiency Virus (HIV). Since then, significant advancements in prevention and treatment, particularly with antiretroviral therapies (ARTs), have improved the quality of life for many living with HIV.

The first treatment to receive approval from FDA was Zidovudine (AZT). Then, a pivotal development occurred in 1995 with the launch of Highly Active Antiretroviral Therapy (HAART), now commonly referred to as combination antiretroviral therapy (cART).

New Innovations, New Horizons, and Ongoing Challenges

Despite significant advancements in HIV treatment, access remains uneven, particularly in sub-Saharan Africa, where 65% of the 39.9 million people living with HIV reside. The introduction of generic antiretroviral therapies in 2001 improved accessibility, yet ARVs only control the virus, and do not cure it, due to latent reservoirs in memory CD4 T cells.

Notable cases, such as the “Berlin patient,” who cleared the virus after two stem cell transplants from a donor with a homozygous CCR5Δ32 mutation (A mutation that prevents HIV from attaching to CD4 T cells), offer hope. Additionally, the immune system of long-term non-progressors (LTNPs) and elite controllers (ECs) manage the virus without treatment.

Current research focuses on stem cell transplantation, genetically engineered CD4 T cells resistant to HIV, and immunity-boosting strategies. However, effective solutions must have lower toxicity than current combination antiretroviral therapy (cART) and be scalable for global reach. Still, fewer than one in three people HIV-positive individuals achieve viral suppression through therapy. Thus, a potential cure would primarily benefit those with an undetectable viral load, impacting less than 25% of individuals in developed countries and even fewer in low-income regions.

Strategies for Closing the Healthcare Gap

To bridge the healthcare gap, we should prioritize:

1. Community Engagement: NGOs should engage with communities by implementing screening programs for at-risk populations, including men who have sex 

with men, individuals who use drugs, and sex workers.

2. Access to Prevention Methods: It is vital to enhance access to proven strategies such as:

   – Preventing mother-to-child HIV transmission.

   – Providing PrEP (pre-exposure prophylaxis) to lower infection risk.

   – Offering PEP (post-exposure prophylaxis).

3. Investment in Antiretroviral Therapy: Continued investment in ART is essential, along with efforts to develop effective vaccines and advanced treatments.

Focusing on these areas will help close the healthcare gap and improve health outcomes for vulnerable populations.

Hopes for the Future

The World Health Organization (WHO) aims to ensure that by 2025, 95% of individuals living with HIV are accurately diagnosed, 95% of those diagnosed receive antiretroviral treatment, and 95% on treatment achieve a suppressed viral load. This initiative will improve health outcomes and significantly reduce HIV transmission rates.

With steadfast commitment and innovative solutions, we are set to close the gaps in HIV treatment and work towards a healthier future for all.

About the author

Hibatallah EL OMARI is a 4th year medical student at Mohammed VI University of Health Sciences in Casablanca, Morocco. She is passionate about scientific research and language learning. Currently, she is serving as the Local Officer On Sexual and Reproductive Health and Rights including HIV and AIDS, for Medec’IN Casa, the local branch of IFMSA-Morocco in Casablanca, driving impactful initiatives on critical sexual health issues.